MAP2K1 and neoplasm: Because they presented the highest phospho-EGFR expression levels, along with high expression levels for phospho-AKT and phospho-MEK1, TCG2, TCG3 and TCG4 tumor lines were expected to benefit from gefitinib-based treatment.